Mondrian Investment Partners LTD Takes Position in Sanofi $SNY

Mondrian Investment Partners LTD purchased a new position in shares of Sanofi (NASDAQ:SNY) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 3,638,606 shares of the company’s stock, valued at approximately $171,742,000. Sanofi makes up 2.9% of Mondrian Investment Partners LTD’s portfolio, making the stock its 8th biggest holding.

Other large investors also recently bought and sold shares of the company. Raymond James Financial Inc. lifted its holdings in shares of Sanofi by 81.3% in the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the last quarter. Franklin Resources Inc. lifted its stake in Sanofi by 9.9% in the second quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock valued at $206,497,000 after buying an additional 384,902 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Sanofi by 4.8% in the second quarter. Envestnet Asset Management Inc. now owns 3,434,999 shares of the company’s stock valued at $165,945,000 after buying an additional 157,605 shares during the last quarter. Equity Investment Corp boosted its holdings in shares of Sanofi by 3.0% in the third quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock valued at $122,139,000 after acquiring an additional 75,255 shares during the period. Finally, Brandes Investment Partners LP grew its position in shares of Sanofi by 9.1% during the second quarter. Brandes Investment Partners LP now owns 2,483,767 shares of the company’s stock worth $119,992,000 after acquiring an additional 208,090 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Citigroup assumed coverage on shares of Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Five equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $62.67.

Sanofi Price Performance

Shares of SNY opened at $46.01 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20. The stock’s 50 day moving average is $47.69 and its two-hundred day moving average is $48.59. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The firm has a market capitalization of $112.22 billion, a PE ratio of 12.78, a P/E/G ratio of 1.20 and a beta of 0.45.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.